Application of MEF2B in identification of secondary follicular-like three-level lymphatic structure in generic solid tumors and prediction of curative effect of immunotherapy or immune combination therapy
By detecting MEF2B markers in pan-solid tumors, the problem of lack of unified standards in the existing technology was solved, and the tertiary lymphatic structure of secondary follicular samples after immunotherapy was successfully predicted, providing scientific treatment guidance, and improving the efficacy and survival rate.
Patent Information
- Application Number
- CN202411384622.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-30
- Publication Date
- 2024-11-15
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The prior art lacks unified standards and markers for detecting and predicting secondary follicular tertiary lymphatic structure after immunotherapy or combined immunotherapy, affecting the evaluation of efficacy and the formulation of personalized treatment strategies.
By detecting MEF2B markers in pan-solid tumors, identifying the tertiary lymphoid structure of secondary follicular samples, and combining single-cell sequencing, spatial omics sequencing and multicolor immunofluorescence staining, the correlation between the existence of MEF2B and the efficacy of immunotherapy is verified. , provide scientific treatment guidance.
Effectively predict the efficacy of immunotherapy or combined immunotherapy, provide personalized treatment plans, improve the scientificity and accuracy of treatment, especially in cancers such as nasopharyngeal carcinoma, which significantly improves the overall survival rate and complete pathological remission of patients. Rate.
Smart Images

Figure CN118962142A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of immunotherapy, and specifically to the application of MEF2B in identifying secondary follicular-like tertiary lymphoid structures in pan-solid tumors and predicting the efficacy of immunotherapy or combined immunotherapy. Background Art
[0002] Immunotherapy represented by PD1 / PDL1 inhibitors has become the main treatment for various types of cancer, including nasopharyngeal carcinoma, esophageal cancer, intestinal cancer, and breast cancer. Currently, relevant markers for immunotherapy in clinical practice include PDL1 expression level, tumor mutation burden (TMB), microsatellite instability (MSI) / mismatch repair deficiency (dMMR), etc., but the predictive ability of each marker in each type of cancer varies, and there is no unified judgment standard or industry specification. For example, the expression level of PDL1 has different measurement indicators (TPS or CPS) and positive judgment criteria in various types of cancer; and MSI / dMMR is only applicable to specific tumors such as colorectal cancer, and there is still a lack of a marker that can be applied to all types of tumors.
[0003] Tertiary lymphoid structures (TLS) refer to structures similar to secondary lymphoid organs (such as lymph nodes) formed in chronic inflammation or tumor microenvironment. TLS provides a place for T cells and B cells to directly respond to immune in the tumor microenvironment, which can support antigen presentation and lymphocyte activation, thereby enhancing local anti-tumor immune response. TLS can also promote stronger immune response by secreting specific chemokines to attract and maintain the accumulation of T cells and B cells at the tumor site. Several studies have found that patients with abundant TLS in tumor tissues tend to have better responses to immunotherapy (such as PD-1 / PD-L1 inhibitors). Therefore, TLS can be used as a potential biomarker to assess the patient's potential to respond to immunotherapy. Secondary follicular-like tertiary lymphoid structure (SFL-TLS) is the final stage of TLS maturation, which is marked by the presence of germinal center (GC)-like structures inside, which can promote B cell maturation, affinity maturation, and antibody production. The presence of SFL-TLS indicates an active immune response in the tumor microenvironment. Detecting the presence and density of SFL-TLS in tumors may help predict patients' response to immunotherapy and guide the development of personalized treatment strategies.
[0004] At present, studies have confirmed that the level of baseline SFL-TLS is related to the efficacy of immunotherapy, and it has been preliminarily found that immunotherapy may induce increased TLS maturity and SFL-TLS in some cancer types, but the relationship between SFL-TLS and efficacy after immunotherapy or combined immunotherapy has not been confirmed. In addition, there is no unified standard for the detection of SFL-TLS. It is mainly performed by immunohistochemical staining (IHC) or multicolor immunofluorescence (mIF) of tissue sections. Commonly used markers indicating SFL-TLS include: CD21 and CD23 (used to detect reticular dendritic cells in GC structure), BCL6 (expressed by germinal center B cells), etc. However, our preliminary results found that CD21, CD23 and BCL6 each have shortcomings and cannot accurately identify SFL-TLS.
[0005] Therefore, we proposed the application of MEF2B in identifying secondary follicular-like tertiary lymphoid structures in pan-solid tumors and predicting the efficacy of immunotherapy or combined immunotherapy, in order to solve the above-mentioned problems. Summary of the invention
[0006] The purpose of the present invention is to provide an application of MEF2B in identifying secondary follicular-like tertiary lymphoid structures in pan-solid tumors and predicting the efficacy of immunotherapy or combined immunotherapy, so as to solve the problems in the current market raised by the above background technology.
[0007] To achieve the above objectives, the present invention provides the use of MEF2B in identifying secondary follicular-like tertiary lymphoid structures in pan-solid tumors and predicting the efficacy of immunotherapy or combined immunotherapy.
[0008] Compared with the prior art, the present invention has the following beneficial effects:
[0009] By detecting the presence of MEF2B+TLS in tumor tissues after immunotherapy, the efficacy of immunotherapy or combined immunotherapy can be predicted for patients, thereby providing scientific guidance for subsequent treatment. BRIEF DESCRIPTION OF THE DRAWINGS
[0010] Figure 1 The present invention studies the flow chart;
[0011] Figure 2 This is the dimensionality reduction diagram of the main cell groups of the present invention;
[0012] Figure 3 This is a schematic diagram for comparing the dimensionality reduction of the main cell populations before and after treatment of the GP cohort and the GP+anti-PD1 cohort of the present invention;
[0013] Figure 4 This is a schematic diagram of the content trend change of the main cell populations of the present invention after GP or GP+anti-PD1 treatment;
[0014] Figure 5 It is a schematic diagram of the correlation analysis between the baseline content of the main cell groups in the GP+anti-PD1 cohort of the present invention and the change range before and after treatment and the tumor regression rate;
[0015] Figure 6 This is the dimensionality reduction diagram of CD4+T cells of the present invention;
[0016] Figure 7 This is a schematic diagram of the content trend change of each CD4+T subset after GP or GP+anti-PD1 treatment of the present invention;
[0017] Figure 8 It is a schematic diagram of the correlation analysis between the baseline content of each CD4+T subgroup in the GP+anti-PD1 cohort of the present invention and the change range before and after treatment and the tumor regression rate;
[0018] Fig. 9 Schematic diagram of multi-target staining to identify CXCR5+CD4T in nasopharyngeal tumor tissues according to the present invention;
[0019] Fig.10 A schematic diagram of TLS for identifying various maturation stages in nasopharyngeal tumor tissue by multi-target staining of the present invention;
[0020] Fig.11 It is a schematic diagram showing the proportion of TLS in different maturity stages before and after treatment of the present invention, and its relationship with the therapeutic effect;
[0021] Fig.12 Schematic diagram of clonality analysis of each CD4+T cell subset of the present invention;
[0022] Fig.13 It is a schematic diagram comparing the clonal expansion of CXCR5+CD4+T cells in each group and the clonal conversion before and after treatment of the present invention;
[0023] Fig.14 This is a schematic diagram of the B cell dimensionality reduction diagram of the present invention;
[0024] Fig.15 This is a schematic diagram of the content trend change of each B cell subset after GP or GP+anti-PD1 treatment of the present invention;
[0025] Fig.16 This is a schematic diagram of the correlation analysis between the baseline content of each B cell subset in the GP+anti-PD1 cohort of the present invention and the change range before and after treatment and the tumor regression rate;
[0026] Fig.17 This is a schematic diagram of the spatial position relationship and changes before and after treatment of CXCR5+CD4T and MEF2B+B cells in nasopharyngeal tumor tissue identified by multi-target staining of the present invention;
[0027] Fig.18 This is a schematic diagram of the comparison of the indication effects of the conventional SFL-TLS marker molecule CD23 and the newly discovered marker molecule MEF2B on SFL-TLS by multi-target staining of the present invention;
[0028] Fig.19 This is a schematic diagram of the comparison of the indication effects of the conventional SFL-TLS marker molecule BCL6 and the newly discovered marker molecule MEF2B on SFL-TLS by multi-target staining of the present invention;
[0029] Fig. 20 This is a schematic diagram of the correlation analysis between the change in the number of MEF2B+B cells before and after treatment and the tumor regression rate of the present invention;
[0030] Fig.21 This is a schematic diagram of the relationship between TLS status and prognosis after immunotherapy combined with chemotherapy in an external cohort of nasopharyngeal carcinoma of the present invention;
[0031] Fig. 22 This is a schematic diagram of the identification of MEF2B+TLS in oral cancer, liver cancer, esophageal cancer, breast cancer, gastric cancer, colorectal cancer, bladder cancer, and non-small cell lung cancer and the changes before and after treatment. DETAILED DESCRIPTION
[0032] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0033] The present invention provides the application of MEF2B in identifying secondary follicle-like tertiary lymphoid structures in pan-solid tumors and predicting the efficacy of immunotherapy or combined immunotherapy.
[0034] 1. Through single-cell sequencing of paired samples before and after a prospective clinical trial to explore the efficacy and safety of combined immunotherapy for locally advanced nasopharyngeal carcinoma (paired nasopharyngeal tumor tissues, metastatic lymph nodes and peripheral blood), and grouping comparative analysis based on efficacy (complete remission CR group vs. non-complete remission Non-CR group), a total of 138 samples were found. It was found that the production of germinal center B cells (GCB) increased significantly after combined immunotherapy, and the increase in GCB was significantly correlated with the degree of tumor shrinkage.
[0035] like Figure 2-Figure 4As shown, a total of 1,008,048 high-quality single-cell data were obtained. After dimensionality reduction and annotation, by comparing the changes in the number of major cell subsets before and after treatment, it was found that CD4+T cells and B cells increased after treatment.
[0036] like Figure 5 As shown, the baseline content of each cell population and the change range before and after treatment were correlated with the tumor regression rate. It was found that the baseline CD8+T cell level and Treg level were positively correlated with the tumor regression rate, but the number decreased after treatment; the expansion of B cells after treatment was associated with better efficacy, suggesting that B cells may be a key factor in the effectiveness of immunochemotherapy.
[0037] like Figure 6-Figure 8 As shown, CD4+T cells were further reduced in dimension, and a total of 14 T cell subsets were obtained, among which CXCR5+CD4T increased after treatment, and the degree of increase was positively correlated with the tumor regression rate.
[0038] 2. The applicant further confirmed through spatial omics sequencing and mIF staining that MEF2B is a marker for GCB, and that positive MEF2B aggregation can indicate SFL-TLS. The interpretation of MEF2B staining results verified the results of single-cell and spatial sequencing, namely, the production of MEF2B+TLS increased significantly after combined immunotherapy in patients with good therapeutic effects.
[0039] like Figure 9-11 As shown, by multi-target staining of CXCR5+CD4T, it was found that before treatment ( Fig. 9 Left) The content of CXCR5+CD4T is low, while after treatment ( Fig. 9 The content of CXCR5+CD4T increased and showed the characteristics of clustered distribution. Combined with the physiological function of CXCR5+CD4T, it is involved in recruiting B cells to form tertiary lymphoid structures (TLS). Therefore, further staining analysis of TLS found that the number of mature TLS (mTLS) in patients in the CR group increased significantly after treatment, while the increase in the Non-CR group was not obvious.
[0040] like Figure 12-13 As shown in the figure, the results of TCR sequencing showed that CXCR5+CD4T was one of the most clonally active CD4T subsets, and the clonality of CXCR5+CD4T in the CR group was further enhanced after treatment, while the clonality of CXCR5+CD4T in the Non-CR group and after chemotherapy alone did not increase significantly.
[0041] The CXCR5+CD4T cells in the CR group underwent more clonal conversion after treatment, and the conversion mainly occurred from CXCL13+CD4T cells to CXCR5+CD4T cells.
[0042] like Figure 14-16As shown in the figure, TLS is a structure formed by T cells around B cells to play a positive immunoregulatory function. Plasma cells and memory B cells that secrete antibodies are produced in TLS to perform B cell-mediated anti-tumor immune regulation. Therefore, further analysis of B cells revealed that germinal center B cells (B_09_MEF2B) decreased after chemotherapy alone, but increased after immunotherapy combined with chemotherapy, and the degree of increase positively reflected the therapeutic efficacy.
[0043] like Fig.17 As shown, further staining and co-localization analysis of MEF2B+B and CXCR5+CD4T revealed that they were scattered before treatment, but distributed around TLS after treatment, which verified the results of single-cell sequencing, namely, the formation of TLS by CXCR5+CD4T and MEF2B+B is a key factor in determining the efficacy of immunochemotherapy.
[0044] like Fig.18 As shown in the figure, the relationship between the maturity of TLS and the therapeutic efficacy was further analyzed. Secondary follicular TLS (SFL-TLS) is TLS in the final maturity stage, which contains germinal center B cells (GCB); while primary follicular TLS (PFL-TLS) does not contain GCB. The traditional markers used to judge SFL-TLS are CD21 and CD23. SFL-TLS is CD21+CD23+, but through staining, it was found that some PFL-TLS also showed the characteristics of CD21+CD23+, but there were no GCB in it, but it was full of immature B cells (IgD+CD27-), which suggests that the traditional CD21 and CD23 are not suitable for judging SFL-TLS in nasopharyngeal carcinoma.
[0045] Further search for markers of SFL-TLS revealed that MEF2B can be used to indicate SFL-TLS with good specificity.
[0046] like Fig.19 As shown in the figure, the staining effect of MEF2B was compared with that of the traditional germinal center cell marker BCL6. It was found that MEF2B had a higher sensitivity for the identification of SFL-TLS than BCL6, and the incidence of false positives was lower than that of BCL6.
[0047] like Fig. 20 As shown, there was a significant positive correlation between the number of MEF2B+B cells and the tumor regression rate.
[0048] like Fig.21 As shown, the results were verified in a cohort of recurrent / metastatic nasopharyngeal carcinoma patients receiving the same treatment regimen (immunotherapy combined with chemotherapy), and it was found that the presence of MEF2B+TLS after treatment was a key factor in determining prognosis. The overall survival rate of patients with MEF2B+TLS after treatment was significantly higher than that of patients without MEF2B+TLS.
[0049] 3. Through staining verification of specimens before and after combined immunotherapy for oral cancer, liver cancer, esophageal cancer, breast cancer, gastric cancer, colorectal cancer, bladder cancer, and non-small cell lung cancer, it was confirmed that MEF2B can be used as a pan-cancer marker to indicate SFL-TLS, and the presence of MEF2B+TLS after treatment is significantly correlated with good therapeutic effects. Patients with MEF2B+TLS after treatment are more likely to achieve pathological complete remission, which is worthy of large-scale clinical promotion and application.
[0050] like Fig. 22 As shown, staining verification was performed in tumor sections of patients with oral cancer, liver cancer, esophageal cancer, breast cancer, gastric cancer, colorectal cancer, bladder cancer, and non-small cell lung cancer who received combined immunotherapy and chemotherapy. It was found that the number of SFL-TLS increased significantly after treatment, and MEF2B can be used as a marker for pan-cancer indication of SFL-TLS.
[0051] In summary, by detecting the presence or absence of MEF2B+TLS in tumor tissues after immunotherapy, the efficacy of immunotherapy or combined immunotherapy in patients can be predicted, thereby providing scientific guidance for subsequent treatment.
[0052] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.
Claims
1. Application of MEF2B in identifying secondary follicular-like tertiary lymphoid structures in a wide range of solid tumors.
2. Application of MEF2B in predicting the efficacy of immunotherapy or combined immunotherapy.
Citation Information
Patent Citations
Tertiary lymphoid structure component marker combination and system for predicting prognosis of nasopharyngeal cancer, and use
WO2024060327A1
Cited By
Biomarker for prognosis evaluation of recurrent nasopharyngeal carcinoma patient and application thereof
CN120490485A
